IP Library Granted Patent US 8,846,409
Granted Patent B2
US 8,846,409 · App. 12/714,907 · Granted Sep 30, 2014

Methods of preparing cannabinoids from plant material

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,409
App. No.
12/714,907
Granted
Sep 30, 2014
Kind
B2
Abstract

The invention relates to methods of preparing cannabinoids in substantially pure form starting from plant material. Also described are substantially pure preparations of various cannabinoids and cannabinoid acids, and also extracts enriched in cannabinoids and cannabinoid acids.

Claims (16)

1. A botanical drug substance (BDS) derived from cannabis plants having a tetrahydrocannabivarin (THCV) content of greater than 70% of total cannabinoids with delta 9 tetrahydrocannabinol (delta 9 THC) being reduced to a level of a minor constituent, which BDS has been obtained by extraction with carbon dioxide followed by a secondary extraction to remove a substantial proportion of non-cannabinoid materials including a substantial proportion of waxes, wax esters and glycerides, unsaturated fatty acid residues, terpenes, carotenes, and flavonoids, and in which the THCV content has been further enriched by separation or fractionation of cannabinoids other than THC, and wherein the delta 9 THC content is less than 2.0% of total cannabinoids.

2. A botanical drug substance as claimed in claim 1 wherein the THCV is delta 9 THCV.

3. A botanical drug substance as claimed in claim 1 , wherein the extraction with carbon dioxide is extraction with subcritical carbon dioxide.

4. A botanical drug substance (BDS) as claimed in claim 1 , wherein the secondary extraction comprises “winterisation”.

5. A botanical drug substance as claimed in claim 1 wherein the BDS is obtained by a method comprising the following steps:

i) Harvesting and decarboxylating cannabis plant material;

ii) Extraction with liquid carbon dioxide (CO2), and removal of CO2 to recover a crude extract;

iii) Dissolution of the crude extract in ethanol followed by chilling of the solution to precipitate unwanted waxes; and

iv) Removal of unwanted waxy material by cold filtration.

6. A botanical drug substance as claimed in claim 1 characterized in that it exhibits an HPLC profile as shown in FIG. 11 (top panel) with a THCV peak at a retention time of 5.9 to 6.2 minutes and a THC peak at a retention time of 9.0 to 10.0 minutes.

7. A botanical drug substance as claimed in claim 1 characterized in that it exhibits a GC profile as shown in FIG. 12 (top panel) with a THCV peak at a retention time of 33.7 to 34.5 minutes and a THC peak at a retention time of 37.2 to 38.1 minutes.

8. A botanical drug substance as claimed in claim 1 comprising at least 75% THCV and less than 2.0% THC of total cannabinoids.

9. A botanical drug substance as claimed in claim 1 comprising a THCV content of greater than 95% of total cannabinoids.

10. A botanical drug substance as claimed in claim 1 comprising less than 1.5%, 1.0% or 0.5% delta 9 THC of total cannabinoids.

11. A botanical drug substance as claimed in claim 1 comprising less than 1.0%, 0.8%, 0.6%, 0.4%, 0.2% or 0.1% cannabidiol (CBD) of total cannabinoids.

12. A botanical drug substance as claimed in claim 1 comprising less than 1.0%, 0.8%, 0.6%, 0.4%, 0.2% or 0.1% cannabinol (CBN).

Assignments (2)
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2010
From: FLOCKHART, IAN R.; WHEATLEY, GARY WILLIAM; DRING, SU; ARCHER, LESLIE
To: GW PHARMA LIMITED
Reel/Frame 024594/0452 →